CYTOCON DB Open is designed for free public use
[Moscow – 12.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, has extended the variety of options to experience its CYTOCON DB with a new way. In general, the database allows to investigate the concentration of multiple species measured in different tissues of patients. Now InSysBio presents its public version entitled “CYTOCON DB Open”.
[Moscow – 10.11.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new access mode to Immune Response Template (IRT) version 3. Now any modeler can experience or get acquainted with IRT via Demo access without the necessity to purchase the license.
DBSolveOptimum 2020 provides extended opportunities for QSP modeling
[Moscow, Russia – 06.10.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases the new version of mathematical simulation workbench DBSolveOptimum 2020. It represents a significantly advanced and extended successor of the well-known simulation software DBSolveOptimum described in the paper [PMID 20698988] published in 2010. DBSolve is a user friendly simulation software package that enables to simplify the development, calibration and analysis of QSP models.
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
InSysBio announces the new version of Cytocon DB 126.96.36.199! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
By using our website, you agree to data collection as described in our website’s data collection policy.